ALKS Alkermes plc.
Price Chart
Executive Summary
Alkermes reported 2025 total revenues of $1.48 billion and diluted GAAP EPS of $1.43, with a 9% year-over-year increase in proprietary product sales. The company expects a GAAP net loss in 2026 due to acquisition-related costs from the Avadel deal, despite projecting revenue growth to $1.73-$1.84 billion. The acquisition of Avadel strengthens its sleep medicine portfolio with LUMRYZ and supports the development of alixorexton.
Key Financial Metrics
Actionable Insight
Monitor the integration of Avadel and the ramp-up of LUMRYZ sales, as the company transitions from profitability to a projected net loss in 2026 due to acquisition accounting. The success of alixorexton's phase 3 trials will be critical for long-term value creation.
Key Facts
- 2025 total revenue was $1.48 billion, down from $1.56 billion in 2024
- 2025 GAAP net income was $242 million, down from $367 million in 2024
- 2026 guidance includes a projected GAAP net loss of $115-$135 million
- 2026 revenue guidance is $1.73-$1.84 billion, representing 17-24% growth
- Acquisition of Avadel closed in February 2026 for $775 million in cash and $1.525 billion in term loans
- LUMRYZ net sales expected to contribute $315-$335 million in 2026
Financial Impact
GAAP net loss of $115-$135 million in 2026 due to $150 million inventory step-up expense and $95-$105 million amortization from Avadel acquisition
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VIVITROL | $467.9M | +2.3% |
| ARISTADA | $370.0M | +6.9% |
| LYBALVI | $346.7M | +23.9% |
Risk Factors
- Integration risks from the Avadel acquisition
- Dilution from $1.525 billion in new debt
- Execution risk in launching and commercializing LUMRYZ
- Clinical development risk for alixorexton
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-068512 |
| Document: alks-20260225.htm | 0001193125-26-068512 |
| Document: alks-ex99_2.htm | 0001193125-26-068512 |
| Document: 0001193125-26-068512-index-headers.html | 0001193125-26-068512 |
| Document: 0001193125-26-068512-index.html | 0001193125-26-068512 |
| Document: 0001193125-26-068512.txt | 0001193125-26-068512 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
Insider Cluster
| $43.38 awaiting T+1 | awaiting T+1 | — | $42.45 (−2.14%) |
|
Jun 1, 2026
8d ago
|
Insider Cluster
| $41.19 $42.71 | ▲ +3.69% | ▲ +4.41% | $42.45 (+3.07%) |
|
May 20, 2026
20d ago
|
8-K
| $36.79 $36.79 | · 0.00% | ▼ −0.45% | $42.45 (+15.39%) |
|
May 13, 2026
27d ago
|
DEFA14A
| $38.26 $37.34 | ▼ −2.40% | ▼ −1.18% | $42.45 (+10.96%) |
|
May 12, 2026
28d ago
|
8-K
| $38.26 $38.76 | ▲ +1.31% | ▲ +0.73% | $42.45 (+10.96%) |
|
May 5, 2026
5w ago
|
8-K
| $36.23 $35.19 | ▼ −2.87% | ▼ −4.26% | $42.45 (+17.18%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $33.26 $34.14 | ▲ +2.65% | ▲ +2.99% | $42.45 (+27.64%) |
|
Mar 2, 2026
14w ago
|
Insider Cluster
| $30.24 $29.19 | ▼ −3.47% | ▼ −2.56% | $42.45 (+40.39%) |
|
Feb 25, 2026
14w ago
|
8-K
| $31.03 $30.75 | ▼ −0.90% | ▼ −0.36% | $42.45 (+36.82%) |
|
Feb 25, 2026
15w ago
|
8-K
| $31.03 $30.75 | ▼ −0.90% | ▼ −0.36% | $42.45 (+36.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access